Literature DB >> 17269160

Vorinostat.

Steven Grant, Chris Easley, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17269160     DOI： 10.1038/nrd2227

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  120 in total

Review 1.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 2.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

3.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

4.  Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

5.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

6.  Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Steven Grant
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

7.  Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

Authors:  Lara S Kallander; David Washburn; Mark A Hilfiker; Hilary Schenck Eidam; Brian G Lawhorn; Joanne Prendergast; Ryan Fox; Sarah Dowdell; Sharada Manns; Tram Hoang; Steve Zhao; Guosen Ye; Marlys Hammond; Dennis A Holt; Theresa Roethke; Xuan Hong; Robert A Reid; Robert Gampe; Hong Zhang; Elsie Diaz; Alan R Rendina; Amy M Quinn; Bob Willette
Journal:  ACS Med Chem Lett       Date:  2018-07-02       Impact factor: 4.345

Review 8.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

9.  Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.

Authors:  Yasmine Haddad; Woonyoung Choi; David J McConkey
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  Optimal Substrate-Trapping Mutants to Discover Substrates of HDAC1.

Authors:  Inosha D Gomes; Mary Kay H Pflum
Journal:  Chembiochem       Date:  2019-04-25       Impact factor: 3.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.